24/7 Market News Snapshot 19 September, 2025 – Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ)
DENVER, Colo., 19 September, 2025 (www.247marketnews.com) – (NASDAQ:PLRZ) are discussed in this article.
Polyrizon Ltd. has demonstrated considerable market resilience, commencing trading today at $1.14, reflecting a robust 6.25% increase amidst favorable investor sentiment. While the stock is currently trading at $1.105 following a minor pullback, the 6.01 million shares exchanged indicate significant trading activity and robust interest. Investors are advised to observe key support levels and resistance near the opening price, as technical indicators suggest potential for future upward momentum.
In a significant development for the biotechnology sector, Polyrizon has submitted its comprehensive pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for the PL-14 Allergy Blocker, an innovative nasal spray designed to alleviate symptoms of nasal allergies. This submission includes detailed manufacturing plans, clinical strategies, and regulatory pathways, underscoring the company’s commitment to ensuring a thorough regulatory approach for potential market approval.
The PL-14 Allergy Blocker is engineered to serve as a non-invasive treatment that forms a physical barrier within the nasal cavity, blocking allergens effectively and providing lasting relief from symptoms associated with allergic rhinitis. This novel solution addresses common issues such as nasal congestion, irritation, and runny noses triggered by allergens including pollen, dust, and pet dander.
CEO Tomer Izraeli articulated the significance of this milestone, stating, “We are pleased to submit this Pre-Sub to the FDA, a crucial step in our journey to bring PL-14 Allergy Blocker to market.” This potential breakthrough addresses a pressing public health issue, with allergic rhinitis affecting a vast number of individuals globally. Polyrizon’s innovative use of its proprietary Capture and Contain™ hydrogel technology positions the company at the leading edge of allergy treatment solutions while reinforcing its dedication to improving patient outcomes. As developments unfold, Polyrizon remains poised to make noteworthy contributions within the healthcare landscape.